GH Research (NASDAQ:GHRS) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded GH Research (NASDAQ:GHRS) from a "hold" to a "sell" rating. Other analysts, including Weiss Ratings and Zacks Research, have also issued negative ratings, while Needham & Company set a "buy" rating with a $19 price target. GH Research has a consensus rating of "Moderate Buy" and a target price of $30.38. The stock traded at $13.50, with a market cap of $702.38 million. Institutional investors hold 56.90% of the stock, and the company focuses on therapies for psychiatric disorders.
GH Research (NASDAQ:GHRS - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday.
- 3 Fast-Growing Stocks Analysts See Doubling in Price
Several other equities research analysts have also commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of GH Research in a research note on Wednesday, October 8th. Needham & Company LLC started coverage on GH Research in a report on Monday, October 13th. They set a "buy" rating and a $19.00 price objective for the company. Finally, Zacks Research downgraded GH Research from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 13th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, GH Research currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.38.
View Our Latest Analysis on GH Research
GH Research Trading Up 0.7%
Shares of GHRS traded up $0.09 during trading hours on Friday, reaching $13.50. The company had a trading volume of 298,857 shares, compared to its average volume of 325,390. GH Research has a 12-month low of $6.72 and a 12-month high of $20.50. The firm has a 50 day simple moving average of $13.45 and a 200-day simple moving average of $13.00. The company has a market capitalization of $702.38 million, a price-to-earnings ratio of -18.24 and a beta of 0.97.
GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). Sell-side analysts forecast that GH Research will post -0.8 earnings per share for the current year.
Hedge Funds Weigh In On GH Research
A number of institutional investors have recently made changes to their positions in GHRS. Cormorant Asset Management LP boosted its stake in shares of GH Research by 238.8% during the first quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company's stock valued at $22,165,000 after acquiring an additional 1,416,439 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in GH Research in the 1st quarter valued at about $8,272,000. Alyeska Investment Group L.P. purchased a new position in GH Research in the 1st quarter valued at about $5,018,000. RA Capital Management L.P. lifted its holdings in GH Research by 3.9% in the 1st quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company's stock valued at $76,599,000 after purchasing an additional 257,959 shares in the last quarter. Finally, CenterBook Partners LP acquired a new stake in shares of GH Research during the 3rd quarter worth about $2,376,000. 56.90% of the stock is owned by institutional investors and hedge funds.
About GH Research
(Get Free Report)GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Read More
- Five stocks we like better than GH Research
- What is the Nasdaq? Complete Overview with History
- Rivian’s Chart Says Go, But Some Analysts Still Say No
- Value Investing: Is it a Good Strategy in 2022? Hint: Always
- e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts
- How to Evaluate a Stock Before Buying
- T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in GH Research Right Now?
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
